AQEEL HASHMI: Open Payments
NPI 1083900955 · RICHMOND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,419 in 73 payments from 13 companies in 2025. Trend: 2023 $491 · 2024 $959 · 2025 $3,419
Food & beverage: $1,778Travel & lodging: $1,632Education: $10
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $2,185 |
| E.R. Squibb & Sons, L.L.C. | 12 | $259 |
| Janssen Pharmaceuticals, Inc | 4 | $171 |
| Teva Pharmaceuticals USA, Inc. | 9 | $160 |
| ABBVIE INC. | 9 | $155 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Alkermes, Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Lundbeck LLC | 2 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
Products named: COBENFY, VRAYLAR, INVEGA SUSTENNA, REXULTI, ABILIFY ASIMTUFII, AUSTEDO XR, ARISTADA, Auvelity.
Industry payments across TX — which companies pay providers there.
